CU20190066A7 - Compuestos derivados de 6-cloro-n-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)pirimidin-4-amina y 6-cloro-n-(4,4-difluorociclohexil)-2-(4-metiltiazol-2-il)pirimidin-4-amina como moduladores del canal de potasio - Google Patents

Compuestos derivados de 6-cloro-n-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)pirimidin-4-amina y 6-cloro-n-(4,4-difluorociclohexil)-2-(4-metiltiazol-2-il)pirimidin-4-amina como moduladores del canal de potasio

Info

Publication number
CU20190066A7
CU20190066A7 CU2019000066A CU20190066A CU20190066A7 CU 20190066 A7 CU20190066 A7 CU 20190066A7 CU 2019000066 A CU2019000066 A CU 2019000066A CU 20190066 A CU20190066 A CU 20190066A CU 20190066 A7 CU20190066 A7 CU 20190066A7
Authority
CU
Cuba
Prior art keywords
pyrimidin
chloro
amine
difluorocyclohexyl
methylthiazol
Prior art date
Application number
CU2019000066A
Other languages
English (en)
Other versions
CU24560B1 (es
Inventor
Dipak Vasantrao Amrutkar
Kelly Foster
Thomas Amos Jacobsen
Martin R Jefson
Gregg F Keaney
Janus Schreiber Larsen
Karin Sandager Nielsen
Original Assignee
Cadent Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadent Therapeutics Inc filed Critical Cadent Therapeutics Inc
Publication of CU20190066A7 publication Critical patent/CU20190066A7/es
Publication of CU24560B1 publication Critical patent/CU24560B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)

Abstract

<p>Se proporcionan compuestos derivados de 6-cloro-N-(4,4-difluorociclohexil)-2-(3-metil-1H-pirazol-1-il)pirimidin-4-amina y 6-cloro-N-(4,4-difluorociclohexil)-2-(4-metiltiazol-2-il)pirimidin-4-amina de fórmula:</p> <p>ESPACIO PARA FÓRMULA</p> <p>útiles para tratar una variedad de enfermedades, trastornos o condiciones, asociados con canales de potasio.</p>
CU2019000066A 2017-01-23 2018-01-23 N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio CU24560B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762449270P 2017-01-23 2017-01-23
PCT/US2018/014792 WO2018136917A1 (en) 2017-01-23 2018-01-23 Potassium channel modulators

Publications (2)

Publication Number Publication Date
CU20190066A7 true CU20190066A7 (es) 2020-03-04
CU24560B1 CU24560B1 (es) 2021-12-08

Family

ID=61188924

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000066A CU24560B1 (es) 2017-01-23 2018-01-23 N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio

Country Status (30)

Country Link
US (4) US9975886B1 (es)
EP (1) EP3571193B1 (es)
JP (1) JP6997197B2 (es)
KR (1) KR102664772B1 (es)
CN (1) CN110198935B (es)
AR (1) AR110770A1 (es)
BR (1) BR112019014814B1 (es)
CL (1) CL2019002031A1 (es)
CO (1) CO2019009060A2 (es)
CU (1) CU24560B1 (es)
CY (1) CY1125463T1 (es)
DK (1) DK3571193T3 (es)
EA (1) EA036668B1 (es)
ES (1) ES2906078T3 (es)
HR (1) HRP20220079T1 (es)
HU (1) HUE057710T2 (es)
IL (1) IL267954B (es)
LT (1) LT3571193T (es)
MX (1) MX376080B (es)
MY (1) MY195123A (es)
PH (1) PH12019501678A1 (es)
PL (1) PL3571193T3 (es)
PT (1) PT3571193T (es)
RS (1) RS62899B1 (es)
SG (1) SG11201905893WA (es)
SI (1) SI3571193T1 (es)
TW (1) TWI751271B (es)
UA (1) UA123810C2 (es)
WO (1) WO2018136917A1 (es)
ZA (1) ZA201904458B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10774064B2 (en) * 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
BR112019014814B1 (pt) * 2017-01-23 2024-03-12 Novartis Ag Compostos, composições farmacêuticas dos mesmos e seus usos no tratamento de doenças associadas à disfunção de canais iônicos de potássio
AU2019366312B2 (en) 2018-10-22 2025-04-24 Novartis Ag Crystalline forms of potassium channel modulators
CN118985622B (zh) * 2024-07-05 2025-12-02 云南大学 一种吡唑类化合物在防治植物根结线虫中的应用

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6059883B2 (ja) 1978-05-08 1985-12-27 北興化学工業株式会社 農園芸用殺菌剤
GB2183243B (en) 1985-10-09 1990-01-24 Nippon Oil Co Ltd Process for preparing oil-soluble nitrogen-containing compounds
WO1989011279A1 (en) 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
LU87304A1 (fr) 1988-07-29 1990-02-07 Oreal Nouveaux derives d'ureylene triamino-2,4,6 pyrimidine oxyde-3,leur preparation et leur utilisation en cosmetique et dermopharmacie
JPH02282251A (ja) 1989-04-24 1990-11-19 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
DE3922735A1 (de) 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
DE4034762A1 (de) 1990-11-02 1992-05-07 Hoechst Ag Pyridylpyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
HU209678B (en) 1992-06-09 1994-10-28 Richter Gedeon Vegyeszet Process for producing biologically active eburnamenin-14-carbonyl-amino derivatives and pharmaceutical compositions containing them
DK72693D0 (da) 1993-06-18 1993-06-18 Lundbeck & Co As H Compounds
CA2133355A1 (en) 1993-10-04 1995-04-05 Itaru Nitta Method for producing polypeptide
AU3785597A (en) 1996-08-14 1998-03-06 Takeda Chemical Industries Ltd. Cyclic urea compounds, their production and use as herbicides
DE19642863A1 (de) 1996-10-17 1998-04-23 Bayer Ag Amide
US6117973A (en) 1997-02-24 2000-09-12 Georgia Tech Research Corp. PNA monomers with electron donor or acceptor
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
JPH11282132A (ja) 1998-03-27 1999-10-15 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の処理方法
JP2000072695A (ja) 1998-08-24 2000-03-07 Sumitomo Pharmaceut Co Ltd 環状化合物
JP2000075449A (ja) 1998-08-31 2000-03-14 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の現像方法
JP2003508509A (ja) 1999-09-04 2003-03-04 アストラゼネカ アクチボラグ ピルビン酸デヒドロゲナーゼの阻害剤としてのアミド
EP1218003A4 (en) 1999-09-13 2004-02-11 David M Swope COMPOSITION AND METHOD FOR REDUCING NEUROLOGICAL SYMPTOMATOLOGY
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US20030181507A1 (en) 2000-06-29 2003-09-25 Jensen Bo Skaaning Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
US20020173524A1 (en) 2000-10-11 2002-11-21 Tularik Inc. Modulation of CCR4 function
MXPA03005120A (es) 2000-12-07 2004-03-10 Cv Therapeutics Inc Compuestos para el incremento de abca-1.
NZ526699A (en) 2001-01-16 2005-03-24 Astrazeneca Ab 8-amino derivatives and their use in treating migraine
BR0206513A (pt) 2001-01-16 2004-01-06 Astrazeneca Ab Composição, métodos de tratamento de um ser humano ou animal que sofre de depressão, ansiedade generalizada, distúrbios da alimentação, demência, distúrbio do p nico, distúrbios do sono, distúrbios gastrointestinais, distúrbios motores, distúrbios endócrinos, vasoespasmo e disfunção sexual, uso de qualquer um dos compostos, composição farmacêutica, e, processo para preparar compostos
MXPA03006250A (es) 2001-01-16 2003-09-22 Astrazeneca Ab Compuestos heterociclicos terapeuticos.
WO2002064096A2 (en) 2001-02-16 2002-08-22 Tularik Inc. Methods of using pyrimidine-based antiviral agents
CN100540538C (zh) * 2001-04-16 2009-09-16 田边三菱制药株式会社 高传导率钙-活化k通道开启剂
EP1270551A1 (en) 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Urea derivatives with antiproteolytic activity
US7378432B2 (en) 2001-09-14 2008-05-27 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
US7012077B2 (en) 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
AU2003212634A1 (en) 2002-03-11 2003-09-22 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
AU2003258630A1 (en) 2002-08-19 2004-03-11 Glaxo Group Limited Pyrimidine derivatives as selective cox-2 inhibitors
US20040087590A1 (en) 2002-08-23 2004-05-06 University Of Connecticut Novel biphenyl and biphenyl-like cannabinoids
GB0311201D0 (en) 2003-05-15 2003-06-18 Merck Sharp & Dohme Therapeutic agents
US7589092B2 (en) 2003-06-20 2009-09-15 Koronis Pharmaceuticals, Incorporated Prodrugs of heteroaryl compounds
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
EP1689722A2 (en) 2003-10-10 2006-08-16 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
CA2541509C (en) 2003-10-17 2014-06-10 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
BRPI0416853A (pt) 2003-11-24 2007-02-13 Hoffmann La Roche pirazolila e imidazolila pirimidinas
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
US20090036448A1 (en) 2004-03-30 2009-02-05 Taisho Pharmecutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
US7745436B2 (en) 2004-04-13 2010-06-29 Synta Pharmaceuticals Corporation Disalt inhibitors of IL-12 production
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
CA2581623A1 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyridine compounds, process for their preparation and compositions containing them
GB0422556D0 (en) 2004-10-11 2004-11-10 Syngenta Participations Ag Novel insecticides
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
WO2006065590A2 (en) 2004-12-16 2006-06-22 Xtl Biopharmaceuticals Inc. Pyridine and pyrimidine antiviral compositions
CA2590110C (en) 2004-12-30 2014-06-03 Exelixis, Inc. Kinase modulators and method of use
US20080249091A1 (en) 2005-01-19 2008-10-09 Benjamin Pelcman Indoles Useful in the Treatment of Inflammation
CA2594665A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
US20090042949A1 (en) 2005-01-19 2009-02-12 Benjamin Pelcman Indoles Useful in the Treatment of Inflammation
ATE501119T1 (de) 2005-01-19 2011-03-15 Biolipox Ab Entzündungshemmende indol-derivate
JP2008527030A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
WO2006097441A1 (en) 2005-03-14 2006-09-21 Neurosearch A/S Potassium channel modulating agents and their medical use
CN101115736A (zh) * 2005-03-14 2008-01-30 神经研究公司 钾通道调节剂和它们的医药用途
US20090036475A1 (en) 2005-03-22 2009-02-05 Neurosearch A/S Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use
JP2008534472A (ja) * 2005-03-22 2008-08-28 ノイロサーチ アクティーゼルスカブ カリウムチャンネル調節剤としてのピラゾリル−ピリミジン及びその医学的使用
US20060156481A1 (en) 2005-03-22 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
DE102005025315A1 (de) 2005-06-02 2006-12-14 Merck Patent Gmbh Ionische Flüssigkeiten mit niedriger Viskosität
US20060281712A1 (en) 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
AR054510A1 (es) 2005-06-14 2007-06-27 Schering Corp Compuestos heterociclicos como inhibidores de aspartil proteasas y composiciones farmaceuticas que los comprenden.
AU2006274733B2 (en) 2005-07-30 2010-09-16 Astrazeneca Ab Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
DE102005043165A1 (de) 2005-09-12 2007-03-22 Merck Patent Gmbh Metallkomplexe
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
FR2892859B1 (fr) 2005-10-27 2008-06-06 Commissariat Energie Atomique Procede de greffage de molecules d'interet sur des surfaces inorganiques, surfaces obtenues et applications
WO2007062222A2 (en) 2005-11-22 2007-05-31 University Of South Florida Inhibition of cell proliferation
RU2008128453A (ru) 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) Соединение n-(5-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
JP2009519342A (ja) 2005-12-12 2009-05-14 ジェネラブズ テクノロジーズ インコーポレーティッド Ｎ−（６員芳香環）−アミド抗ウイルス化合物
EP1966184B1 (en) 2005-12-20 2010-08-25 NeuroSearch A/S Pyridinyl-quinazoline derivatives and their medical use
BRPI0709289A2 (pt) 2006-03-13 2011-07-05 Perkinelmer Las Inc substrato para análise espectrométrica de massa de uma enzima, processo para analise espectrométrica de massa de uma enzima, embalagem comercial e método para usar o dito substrato
WO2007128462A1 (en) 2006-05-02 2007-11-15 Chris Rundfeldt Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
CA2659391A1 (en) 2006-08-03 2008-02-07 Prosensa Technologies B.V. Antibiotic composition
US20110144140A1 (en) 2006-09-07 2011-06-16 Eriksen Birgitte L Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
AU2007304195A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
WO2008052861A2 (de) 2006-10-10 2008-05-08 Proionic Production Of Ionic Substances Gmbh & Co Keg Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten
JP2010510246A (ja) 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション アミド抗ウイルス化合物
CN101679371A (zh) 2006-12-04 2010-03-24 艾美罗股份公司 作为腺苷受体拮抗剂的取代的嘧啶
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
AU2008213808B2 (en) 2007-02-06 2011-11-10 Novartis Ag PI 3-kinase inhibitors and methods of their use
CN101622231B (zh) 2007-02-28 2013-12-04 艾德维纳斯医疗私人有限公司 作为葡糖激酶激活剂的2，2，2-三取代的乙酰胺衍生物、它们的制造方法和药学应用
WO2008110891A2 (en) 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
US20100105705A1 (en) 2007-03-28 2010-04-29 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
EP2142547A1 (en) 2007-03-28 2010-01-13 NeuroSearch A/S Purinyl derivatives and their use as potassium channel modulators
WO2008125811A1 (en) 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
JP5111039B2 (ja) 2007-09-27 2012-12-26 富士フイルム株式会社 重合性化合物、重合開始剤、および染料を含有する光硬化性組成物
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
EP2251001A4 (en) 2008-02-08 2013-01-09 Shiseido Co Ltd SKIN BLEACHING AND EXTERNAL PREPARATION FOR THE SKIN
WO2009105881A1 (en) 2008-02-28 2009-09-03 Saint Mary's University Ionic liquids comprising ligands containing positively charged heterocyclic ring useful as catalyst and for metal extractions
JP2011515462A (ja) 2008-03-27 2011-05-19 アウククランド ウニセルビセス リミテッド 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用
EP2280948A1 (en) 2008-04-09 2011-02-09 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
WO2009152902A2 (en) 2008-05-28 2009-12-23 Merck Patent Gmbh, Ionic liquids
UY31885A (es) 2008-06-11 2010-01-29 Astrazeneca Ab Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
DE102008031480A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Salze enthaltend ein Pyrimidincarbonsäure-Derivat
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
CN102177154A (zh) * 2008-09-02 2011-09-07 神经研究公司 吡唑基-嘧啶衍生物及其作为钾通道调节剂的应用
CN101684098A (zh) 2008-09-24 2010-03-31 中国科学院上海药物研究所 一类5-脂氧酶抑制剂及其制备方法、药物组合物和应用
US8268838B2 (en) 2008-09-26 2012-09-18 Neurosearch A/S Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
AR074870A1 (es) 2008-12-24 2011-02-16 Palau Pharma Sa Derivados de pirazolo (1,5-a ) piridina
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
CA2937222C (en) 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
US8377639B2 (en) 2009-06-26 2013-02-19 University Of Massachusetts Compounds for modulating RNA binding proteins and uses therefor
ME02443B (me) 2009-07-08 2016-09-20 Baltic Bio Ab Derivati 1,2,4-tiazolidin-3-ona i njihova upotreba u liječenju kancera
WO2011008931A2 (en) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
JP5728683B2 (ja) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
AR078278A1 (es) 2009-09-09 2011-10-26 Vifor Int Ag Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
US9181414B2 (en) 2009-11-13 2015-11-10 Plastipak Packaging, Inc. Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions
FR2954317B1 (fr) 2009-12-23 2012-01-27 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
AT509266B1 (de) 2009-12-28 2014-07-15 Univ Wien Tech Substituierte pyridine und pyrimidine
KR101939704B1 (ko) 2010-03-01 2019-01-17 지티엑스, 인코포레이티드 암 치료용 화합물
NZ603876A (en) 2010-05-13 2015-02-27 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
KR20120018236A (ko) 2010-07-23 2012-03-02 현대약품 주식회사 치환된 피리미디닐 유도체 및 이의 제조방법
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
EP2606033A1 (de) 2010-08-20 2013-06-26 Grünenthal GmbH Substituierte cyclische carboxamid- und harnstoff-derivate als liganden des vanilloid-rezeptors
BR112013004690A2 (pt) * 2010-08-27 2016-05-10 Gruenenthal Gmbh 2-oxo-e 2-tioxo-di-hidroquinolina-3-carboxamidas substituídas como moduladores kcnq2/3
CN103201891A (zh) 2010-09-30 2013-07-10 巴斯夫欧洲公司 电解质添加剂
US9394290B2 (en) 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
US9290591B2 (en) 2011-02-08 2016-03-22 President And Fellows Of Harvard College Iron complexes and methods for polymerization
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102731492B (zh) 2011-03-30 2016-06-29 江苏恒瑞医药股份有限公司 环己烷类衍生物、其制备方法及其在医药上的应用
WO2012154880A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
RS58718B1 (sr) 2011-05-12 2019-06-28 Proteostasis Therapeutics Inc Regulatori proteostaze
SG195086A1 (en) 2011-05-31 2013-12-30 Merck Patent Gmbh Compounds containing hydrido-tricyano-borate anions
WO2012167171A2 (en) 2011-06-03 2012-12-06 Massachusetts Institute Of Technology Z-selective ring-closing metathesis reactions
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
JP2013020223A (ja) 2011-06-17 2013-01-31 Fujifilm Corp 高分子フィルム、セルロースエステルフィルム、偏光板、及び液晶表示装置
AU2012302022A1 (en) 2011-08-29 2014-03-13 Ptc Therapeutics, Inc. Antibacterial compounds and methods for use
JP5741850B2 (ja) 2011-09-13 2015-07-01 コニカミノルタ株式会社 光学フィルム、それを含む偏光板および液晶表示装置
JP5857713B2 (ja) 2011-12-15 2016-02-10 コニカミノルタ株式会社 光学フィルム、偏光板、及び液晶表示装置
WO2013120040A1 (en) 2012-02-10 2013-08-15 Children's Medical Center Corporation Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy
DE102012006896A1 (de) 2012-04-05 2013-10-10 Merck Patent Gmbh Silikate mit organischen Kationen
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
FR2992317B1 (fr) 2012-06-22 2016-05-13 Diverchim Procede de preparation de peptides chiraux
CN104662002A (zh) 2012-07-27 2015-05-27 比亚尔-珀特拉和Ca股份公司 取代脲类化合物的合成方法
US20150246024A1 (en) 2012-08-20 2015-09-03 The University Of Chicago Methods and compositions for inhibiting gram positive bacteria
WO2014031872A2 (en) 2012-08-23 2014-02-27 The Broad Institute, Inc. Small molecule inhibitors for treating parasitic infections
DK2897948T3 (en) 2012-09-18 2016-12-05 Heptares Therapeutics Ltd BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS
DE102012021452A1 (de) 2012-10-31 2014-04-30 Merck Patent Gmbh Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion
EP2920148B1 (en) 2012-11-16 2019-06-12 The Regents of the University of California Pictet-spengler ligation for protein chemical modification
ES2469290B2 (es) 2012-12-17 2015-01-26 Ocupharm Diagnostics S.L. Mejora en la aplicación tópica de fármacos oculares mediante la administración de nucleótidos
US9279094B2 (en) 2012-12-21 2016-03-08 Afton Chemical Corporation Friction modifiers for use in lubricating oil compositions
US9499762B2 (en) 2012-12-21 2016-11-22 Afton Chemical Corporation Additive compositions with a friction modifier and a detergent
JP6450323B2 (ja) 2013-01-07 2019-01-09 ユニバーシティ オブ サザン カリフォルニア デオキシウリジントリホスファターゼ阻害剤
WO2014108487A1 (en) 2013-01-10 2014-07-17 Universite D'aix-Marseille P-stereogenic chiral precursor of chiral ligands and use thereof
US9487472B2 (en) 2013-02-26 2016-11-08 President And Fellows Of Harvard College Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer
HUE041544T2 (hu) 2013-03-12 2019-05-28 Vertex Pharma DNS-PK inhibitorok
EP2981522A4 (en) 2013-04-05 2016-08-31 Salk Inst For Biological Studi PPAR AGONISTS
CN105359290A (zh) 2013-07-02 2016-02-24 默克专利有限公司 有机电致发光器件
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20160250221A1 (en) 2013-07-25 2016-09-01 Fondazione Telethon Inhibitors of fapp2 and uses thereof
WO2015013715A2 (en) 2013-07-26 2015-01-29 Thr Regents Of The University Of California C-h fluorination of heterocycles with silver (ii) fluoride
WO2015031725A1 (en) 2013-08-30 2015-03-05 President And Fellows Of Harvard College Transition metal-catalyzed imidation of arenes
DE102013016324A1 (de) 2013-10-04 2015-04-09 Merck Patent Gmbh Perfluoralkylfluor- oder Perfluoralkylchlorgermanate
KR20160063366A (ko) 2013-10-21 2016-06-03 메르크 파텐트 게엠베하 Btk 저해제로서 헤테로아릴 화합물 및 이들의 용도
WO2015069752A1 (en) 2013-11-05 2015-05-14 The Regents Of The University Of California Acetylcholine binding protein ligands, cooperative nachr modulators and methods for making and using
CN103626741A (zh) 2013-11-26 2014-03-12 苏州大学 具有腺苷受体拮抗剂活性的杂环氨基嘧啶化合物
ES2906062T3 (es) 2013-11-29 2022-04-13 Proionic Gmbh Procedimiento para la unión de un material termoplástico por medio de radiación de microondas
EP3076789A4 (en) 2013-12-04 2017-11-22 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
RU2016141934A (ru) 2014-04-04 2018-05-07 Сирос Фармасьютикалз, Инк. Ингибиторы циклин-зависимой киназы 7 (cdk7)
US10308648B2 (en) 2014-10-16 2019-06-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
GB201502412D0 (en) 2015-02-13 2015-04-01 Canbex Therapeutics Ltd Therapeutic use
WO2017044889A1 (en) 2015-09-10 2017-03-16 The Regents Of The University Of California Lrh-1 modulators
US20170299609A1 (en) 2016-04-18 2017-10-19 Wright State University Treatment of amyotrophic lateral sclerosis with sk channel activators
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
US20170355708A1 (en) 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
BR112019014814B1 (pt) 2017-01-23 2024-03-12 Novartis Ag Compostos, composições farmacêuticas dos mesmos e seus usos no tratamento de doenças associadas à disfunção de canais iônicos de potássio
US20180207138A1 (en) 2017-01-23 2018-07-26 Cadent Therapeutics, Inc. Methods for the treatment of tremors by positive modulation of sk channels

Also Published As

Publication number Publication date
US20180215746A1 (en) 2018-08-02
IL267954A (en) 2019-09-26
ZA201904458B (en) 2023-04-26
US20210380571A1 (en) 2021-12-09
TWI751271B (zh) 2022-01-01
US9975886B1 (en) 2018-05-22
HUE057710T2 (hu) 2022-05-28
SI3571193T1 (sl) 2022-04-29
JP6997197B2 (ja) 2022-01-17
EA036668B1 (ru) 2020-12-07
MX2019008682A (es) 2019-09-18
BR112019014814A2 (pt) 2020-02-27
HRP20220079T1 (hr) 2022-04-15
UA123810C2 (uk) 2021-06-02
AR110770A1 (es) 2019-05-02
MX376080B (es) 2025-03-07
PH12019501678A1 (en) 2020-06-01
US20190352293A1 (en) 2019-11-21
CY1125463T1 (el) 2024-02-16
BR112019014814B1 (pt) 2024-03-12
EA201991488A1 (ru) 2019-12-30
PT3571193T (pt) 2022-03-25
RS62899B1 (sr) 2022-03-31
EP3571193B1 (en) 2021-12-01
CL2019002031A1 (es) 2019-10-04
KR102664772B1 (ko) 2024-05-10
MY195123A (en) 2023-01-11
SG11201905893WA (en) 2019-08-27
PL3571193T3 (pl) 2022-04-25
US10717728B2 (en) 2020-07-21
IL267954B (en) 2022-02-01
LT3571193T (lt) 2022-02-10
US10351553B2 (en) 2019-07-16
EP3571193A1 (en) 2019-11-27
CN110198935B (zh) 2022-05-31
TW201838985A (zh) 2018-11-01
CO2019009060A2 (es) 2019-08-30
ES2906078T3 (es) 2022-04-13
WO2018136917A1 (en) 2018-07-26
KR20190110572A (ko) 2019-09-30
JP2020504165A (ja) 2020-02-06
CU24560B1 (es) 2021-12-08
CN110198935A (zh) 2019-09-03
DK3571193T3 (da) 2022-01-17

Similar Documents

Publication Publication Date Title
CL2016002382A1 (es) Derivados de quinoxalina útiles como moduladores de fgfr quinasa
PH12020550523A1 (en) Modulators of the integrated stress pathway
CR20210592A (es) Moduladores de la vía integrada del estrés
MX383652B (es) Moduladores de la vía de estrés integrada.
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
MX390347B (es) Compuestos de aminotiazol como inhibidores de c-kit.
AU2017261336A1 (en) Modulators of the integrated stress pathway
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
MX2017008520A (es) Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
AU2017260374A1 (en) Modulators of the integrated stress pathway
GEP20186933B (en) Substituted dihydroisoquinoline compounds
MX2020011478A (es) Formas solidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il) -1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmaceuticas y usos.
EA201990400A1 (ru) Соединения и композиции и их применение
MX373234B (es) Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central.
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
MX388026B (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
NZ746468A (en) Methods of treating ocular conditions
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
CR20170591A (es) Benzamidas sustituidas y métodos para utilizarlas
MX378739B (es) Compuestos de 2-oxindol.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
CU24560B1 (es) N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio
MX2017007955A (es) Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas.
MX2021000432A (es) Formas solidas de compuestos de 5,6-dihidro-6-fenilbenzo[f]isoquin olin-2-amina sustituidos.
GEAP202215506A (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors